We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: Meta-analysis of randomized trials.
- Authors
Cuppone, Federica; Bria, Emilio; Giannarelli, Diana; Vaccaro, Vanja; Milella, Michele; Nisticò, Cecilia; Ruggeri, Enzo Maria; Sperduti, Isabella; Bracarda, Sergio; Pinnarò, Paola; Lanzetta, Gaetano; Muti, Paola; Cognetti, Francesco; Carlini, Paolo
- Abstract
Background: Hormone therapy plus radiotherapy significantly decreases recurrences and mortality of patients affected by locally advanced prostate cancer. In order to determine if difference exists according to the hormonal treatment duration, a literature-based meta-analysis was performed. Methods: Relative risks (RR) were derived through a random-effect model. Differences in primary (biochemical failure, BF; cancer-specific survival, CSS), and secondary outcomes (overall survival, OS; local or distant recurrence, LR/DM) were explored. Absolute differences (AD) and the number needed to treat (NNT) were calculated. Heterogeneity, a meta-regression for clinic-pathological predictors and a correlation test for surrogates were conducted. Results: Five trials (3,424 patients) were included. Patient population ranged from 267 to 1,521 patients. The longer hormonal treatment significantly improves BF (with significant heterogeneity) with an absolute benefit of 10.1%, and a non significant trend in CSS. With regard to secondary end-points, the longer hormonal treatment significantly decrease both the LR and the DM with an absolute difference of 11.7% and 11.5%. Any significant difference in OS was observed. None of the three identified clinico-pathological predictors (median PSA, range 9.5-20.35, Gleason score 7-10, 27-55% patients/trial, and T3-4, 13-77% patients/trial), did significantly affect outcomes. At the meta-regression analysis a significant correlation between the overall treatment benefit in BF, CSS, OS, LR and DM, and the length of the treatment was found (p=0.03). Conclusions: Although with significant heterogeneity (reflecting different patient' risk stratifications), a longer hormonal treatment duration significantly decreases biochemical, local and distant recurrences, with a trend for longer cancer specific survival.
- Subjects
CANCER hormone therapy; CANCER radiotherapy; PROSTATE-specific antigen; META-analysis; MULTIVARIATE analysis
- Publication
BMC Cancer, 2010, Vol 10, p675
- ISSN
1471-2407
- Publication type
Article
- DOI
10.1186/1471-2407-10-675